Ad
related to: dabrafenib trametinib suspension- Contact a Rep
Learn why OJEMDA might be right
for your pediatric patients
- Read the Access Brochure
Learn about reimbursement support
and access for OJEMDA
- See Instructions for Use
Help your patients get started
with OJEMDA. Read this guidance.
- Sign Up for Updates
Sign up to stay informed
about the latest data
- Contact a Rep
Search results
Results from the WOW.Com Content Network
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [ 6 ] [ 7 ] It is a MEK inhibitor drug with anti-cancer activity. [ 8 ]
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
Dabrafenib and trametinib have been approved as tissue-agnostic drugs for solid tumors that are B-RAF positive. [ 16 ] Tissue-agnostic cancer drugs that are under development as of May 2022 [update] include Selitrectinib (Loxo-195) and anti- ERBB3 antibodies.
Dabrafenib: Dostarlimab: Eflornithine: Elranatamab: To treat relapsed or refractory multiple myeloma after at least four lines of therapy [4] Enfortumab vedotin: Iptacopan: To treat paroxysmal nocturnal hemoglobinuria [4] Ivosidenib: Lecanemab: To treat Alzheimer's disease [4] Miglustat: Nedosiran
In January 2015, trial results compared vemurafenib with the combination of dabrafenib and trametinib for metastatic melanoma. [22] Society and culture
Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer. [1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). [2]
This page was last edited on 23 December 2024, at 06:18 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Tovorafenib, sold under the brand name Ojemda, is a medication used for the treatment of glioma. [1] [2] It is a kinase inhibitor.[1]The most common adverse reactions include rash, hair color changes, fatigue, viral infection, vomiting, headache, hemorrhage, pyrexia, dry skin, constipation, nausea, dermatitis acneiform, and upper respiratory tract infection. [3]
Ad
related to: dabrafenib trametinib suspension